$CASI
CASI Pharmaceuticals, Inc. Stock $casi

$casi Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 20-F Financial Statement

#000155837024004190 Filed on March 28, 2024

Income Statement

Concept	2023 Q4	2023 Q1	2023
Revenue	$6.874M	$8.347M	$33.88M
YoY Change	-54.95%	-7.89%	-21.41%
Cost Of Revenue	$2.815M	$3.378M	$13.83M
YoY Change	-34.11%	-10.11%	-12.64%
Gross Profit	$4.059M	$4.969M	$20.05M
YoY Change	-63.06%	-6.32%	-26.5%
Gross Profit Margin	59.05%	59.53%	59.19%
Selling, General & Admin	$11.57M	$9.707M	$41.84M
YoY Change	-2.28%	12.85%	10.75%
% of Gross Profit	285.05%	195.35%	208.64%
Research & Development	$2.314M	$2.534M	$9.861M
YoY Change	-45.53%	-36.52%	-38.35%
% of Gross Profit	57.01%	51.0%	49.18%
Depreciation & Amortization			$3.741M
YoY Change			211.75%
% of Gross Profit			18.66%
Operating Expenses	$7.518M	$12.24M	$45.33M
YoY Change	-53.27%	-2.8%	-15.69%
Operating Profit	-$3.459M	-$7.272M	-$25.28M
YoY Change	-32.19%	-0.25%	-25.72%
Interest Expense	$631.0K	$121.0K	$233.0K
YoY Change	-202.44%	-110.54%
% of Operating Profit
Other Income/Expense, Net	-$1.135M	$1.337M	$764.0K
YoY Change	6993.75%	3418.42%	1636.36%
Pretax Income	-$5.972M	-$5.814M	-$26.29M
YoY Change	-63.84%	-30.79%	112.74%
Income Tax	-$81.00K	$0.00	-$81.00K
% Of Pretax Income
Net Earnings	-$6.077M	-$6.009M	-$26.96M
YoY Change	-68.89%	-30.1%	-34.27%
Net Earnings / Revenue	-88.41%	-71.99%	-79.58%
Basic Earnings Per Share			-$2.02
Diluted Earnings Per Share	-$0.45	-$0.45	-$2.02
COMMON SHARES
Basic Shares Outstanding	13.38M		13.36M
Diluted Shares Outstanding			13.36M

Balance Sheet

Concept	2023 Q4	2023 Q1	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$18.76M	$19.18M	$18.76M
YoY Change	-62.39%	-48.84%	-62.39%
Cash & Equivalents	$17.08M	$16.59M	$17.08M
Short-Term Investments	$1.675M	$2.585M	$1.675M
Other Short-Term Assets	$14.57M	$27.74M	$14.57M
YoY Change	228.4%	1876.0%	228.4%
Inventory	$15.88M	$8.565M	$15.88M
Prepaid Expenses
Receivables	$9.551M	$11.11M	$9.551M
Other Receivables	$587.0K	$0.00	$587.0K
Total Short-Term Assets	$59.34M	$66.59M	$59.34M
YoY Change	-19.18%	26.38%	-19.18%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.63M	$12.41M	$11.63M
YoY Change	-1.67%	-46.95%	-12.06%
Goodwill
YoY Change
Intangibles	$1.839M
YoY Change	73.0%
Long-Term Investments	$1.686M	$4.329M	$1.686M
YoY Change	-61.66%	-89.26%	-61.66%
Other Assets	$766.0K	$4.252M	$766.0K
YoY Change	-27.46%	237.46%	-81.41%
Total Long-Term Assets	$15.92M	$21.80M	$15.92M
YoY Change	-30.19%	-71.64%	-30.19%
TOTAL ASSETS
Total Short-Term Assets	$59.34M	$66.59M	$59.34M
Total Long-Term Assets	$15.92M	$21.80M	$15.92M
Total Assets	$75.27M	$88.40M	$75.27M
YoY Change	-21.79%	-31.77%	-21.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.438M	$2.825M	$4.438M
YoY Change	34.93%	-60.61%	34.93%
Accrued Expenses	$12.29M	$10.53M	$12.29M
YoY Change	3.99%	57.17%	3.99%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$16.73M	$14.04M	$16.73M
YoY Change	-1.64%	1.19%	-1.64%
LONG-TERM LIABILITIES
Long-Term Debt	$18.90M	$0.00	$18.90M
YoY Change
Other Long-Term Liabilities	$15.48M	$12.14M	$15.48M
YoY Change	25.9%	-28.52%	25.9%
Total Long-Term Liabilities	$34.38M	$12.14M	$34.38M
YoY Change	179.56%	-28.52%	179.56%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.73M	$14.04M	$16.73M
Total Long-Term Liabilities	$34.38M	$12.14M	$34.38M
Total Liabilities	$51.10M	$48.82M	$51.10M
YoY Change	74.4%	-10.55%	-1.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$660.8M
YoY Change	3.7%
Common Stock	$1.000K
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$9.604M
YoY Change	2.94%
Treasury Stock Shares
Shareholders Equity	$24.17M	$39.58M	$24.17M
YoY Change
Total Liabilities & Shareholders Equity	$75.27M	$88.40M	$75.27M
YoY Change	-21.79%	-31.77%	-21.79%

Cashflow Statement

Concept	2023 Q4	2023 Q1	2023
OPERATING ACTIVITIES
Net Income	-$6.077M	-$6.009M	-$26.96M
YoY Change	-68.89%	-30.1%	-34.27%
Depreciation, Depletion And Amortization			$3.741M
YoY Change			211.75%
Cash From Operating Activities			-$19.97M
YoY Change			-5.32%
INVESTING ACTIVITIES
Capital Expenditures			$2.241M
YoY Change			-60.07%
Acquisitions
YoY Change
Other Investing Activities			-$7.432M
YoY Change			-120.21%
Cash From Investing Activities			-$9.673M
YoY Change			-131.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			-$169.0K
YoY Change			-105.17%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities			-907.0K
YoY Change			-72.24%
NET CHANGE
Cash From Operating Activities			-19.97M
Cash From Investing Activities			-9.673M
Cash From Financing Activities			-907.0K
Net Change In Cash			-30.55M
YoY Change			-463.31%
FREE CASH FLOW
Cash From Operating Activities			-$19.97M
Capital Expenditures			$2.241M
Free Cash Flow			-$22.21M
YoY Change			-16.82%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q4	us-gaap	Other Receivable After Allowance For Credit Loss Related Party Type Extensible Enumeration OtherReceivableAfterAllowanceForCreditLossRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001962738
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2022Q4	us-gaap	Other Receivable After Allowance For Credit Loss Related Party Type Extensible Enumeration OtherReceivableAfterAllowanceForCreditLossRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q4	us-gaap	Other Receivable After Allowance For Credit Loss Related Party Type Extensible Enumeration OtherReceivableAfterAllowanceForCreditLossRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022	casi	Share Based Payment Cash Received From Stock Option Exercises ShareBasedPaymentCashReceivedFromStockOptionExercises
CY2023	dei	Document Type DocumentType	20-F
CY2023	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-41666
CY2023	dei	Entity Registrant Name EntityRegistrantName	CASI PHARMACEUTICALS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1701-1702, China Central Office Tower 1
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	No. 81 Jianguo Road Chaoyang District
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Beijing
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	100025
CY2023	dei	Entity Address Country EntityAddressCountry	CN
CY2023	dei	Security12b Title Security12bTitle	Ordinary shares, par value US$0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	CASI
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13378175
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Auditor Firm AuditorFirmId	1186
CY2023	dei	Auditor Name AuditorName	KPMG Huazhen LLP
CY2023	dei	Auditor Location AuditorLocation	Beijing, China
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17083000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47112000
CY2023Q4	casi	Investment Equity Securities Fair Value InvestmentEquitySecuritiesFairValue	1675000
CY2022Q4	casi	Investment Equity Securities Fair Value InvestmentEquitySecuritiesFairValue	2763000
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	12011000
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	1462000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9551000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12973000
CY2023Q4	us-gaap	Other Receivables OtherReceivables	587000
CY2023Q4	us-gaap	Inventory Net InventoryNet	15877000
CY2022Q4	us-gaap	Inventory Net InventoryNet	6138000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2560000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2975000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	59344000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	73423000
CY2022Q4	casi	Term Deposit Noncurrent TermDepositNoncurrent	3065000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9241000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11831000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1839000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1063000
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	1686000
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	4398000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2392000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1398000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	766000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1056000
CY2023Q4	us-gaap	Assets Assets	75268000
CY2022Q4	us-gaap	Assets Assets	96234000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4438000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3289000
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	12288000
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	11816000
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	1900000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16726000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17005000
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	18895000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	15482000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	12297000
CY2023Q4	us-gaap	Liabilities Liabilities	51103000
CY2022Q4	us-gaap	Liabilities Liabilities	29302000
CY2022Q4	us-gaap	Redeemable Noncontrolling Interest Equity Redemption Value RedeemableNoncontrollingInterestEquityRedemptionValue	22358000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13790127
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13733459
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13378175
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13457625
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	695785000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	691766000
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	411952
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	24165000
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	275834
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	9604000
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	9330000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1200000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-703000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-660817000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-637160000
CY2023	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-581000
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-8895000
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	5660000
CY2022	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	5325000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	44574000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	75268000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	96234000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	33879000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38047000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30020000
CY2022	casi	Sublicensing Revenue From Related Party SublicensingRevenueFromRelatedParty	5000000
CY2023	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	0
CY2022	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	60000
CY2021	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	148000
CY2023	us-gaap	Revenues Revenues	33879000
CY2022	us-gaap	Revenues Revenues	43107000
CY2021	us-gaap	Revenues Revenues	30168000
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	13827000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	15827000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	12557000
CY2023	us-gaap	Gross Profit GrossProfit	20052000
CY2022	us-gaap	Gross Profit GrossProfit	27280000
CY2021	us-gaap	Gross Profit GrossProfit	17611000
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	9861000
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	15996000
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	14422000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25387000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23449000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23701000
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	16450000
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	14326000
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	14705000
CY2023	us-gaap	Other Operating Income OtherOperatingIncome	6366000
CY2021	casi	Research And Development In Process1 ResearchAndDevelopmentInProcess1	6555000
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-2058000
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-65000
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	200000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	3241000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	321000
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	8724000
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	45132000
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	61312000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	59127000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-25080000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-34032000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-41516000
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	614000
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	127000
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	321000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	764000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	44000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	558000
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-88000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24154000
CY2023	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	-2009000
CY2021	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	-865000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-26292000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-37431000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-35842000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-81000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1980000
CY2023	casi	Income Loss From Continuing Operations Before Equity Method Investments Noncontrolling Interest After Tax IncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsNoncontrollingInterestAfterTax	-26211000
CY2022	casi	Income Loss From Continuing Operations Before Equity Method Investments Noncontrolling Interest After Tax IncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsNoncontrollingInterestAfterTax	-39411000
CY2021	casi	Income Loss From Continuing Operations Before Equity Method Investments Noncontrolling Interest After Tax IncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsNoncontrollingInterestAfterTax	-35842000
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-48000
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-846000
CY2023	us-gaap	Profit Loss ProfitLoss	-26259000
CY2022	us-gaap	Profit Loss ProfitLoss	-40257000
CY2021	us-gaap	Profit Loss ProfitLoss	-35842000
CY2023	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-2602000
CY2022	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-8740000
CY2021	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-700000
CY2023	casi	Redeemable Noncontrolling Interest Accretion To Redemption Value Adjustment RedeemableNoncontrollingInterestAccretionToRedemptionValueAdjustment	3281000
CY2022	casi	Redeemable Noncontrolling Interest Accretion To Redemption Value Adjustment RedeemableNoncontrollingInterestAccretionToRedemptionValueAdjustment	9497000
CY2021	casi	Redeemable Noncontrolling Interest Accretion To Redemption Value Adjustment RedeemableNoncontrollingInterestAccretionToRedemptionValueAdjustment	1512000
CY2023	casi	Deemed Dividends Adjustment DeemedDividendsAdjustment	22000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-26960000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-41014000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-36654000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.02
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.02
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.01
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.01
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.69
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.69
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13360185
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13360185
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13647455
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13647455
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13610441
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13610441
CY2023	us-gaap	Profit Loss ProfitLoss	-26259000
CY2022	us-gaap	Profit Loss ProfitLoss	-40257000
CY2021	us-gaap	Profit Loss ProfitLoss	-35842000
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1118000
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-4513000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1977000
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-27377000
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-44770000
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-33865000
CY2023	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-3223000
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-10596000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-34174000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33777000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	81540000
CY2021	casi	Stock Issued During Period Value Common Stock Pursuant To Financing Agreements StockIssuedDuringPeriodValueCommonStockPursuantToFinancingAgreements	32500000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	2019000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7770000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	-1365000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-36654000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	84502000
CY2022	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	3267000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7010000
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	2657000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-41014000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	44574000
CY2023	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	278000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	109000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7217000
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	497000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-26960000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	24165000
CY2023	us-gaap	Profit Loss ProfitLoss	-26259000
CY2022	us-gaap	Profit Loss ProfitLoss	-40257000
CY2021	us-gaap	Profit Loss ProfitLoss	-35842000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2454000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1212000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	468000
CY2023	casi	Amortization Of Intangible Assets And Held For Sale AmortizationOfIntangibleAssetsAndHeldForSale	1287000
CY2022	casi	Amortization Of Intangible Assets And Held For Sale AmortizationOfIntangibleAssetsAndHeldForSale	1210000
CY2021	casi	Amortization Of Intangible Assets And Held For Sale AmortizationOfIntangibleAssetsAndHeldForSale	1347000
CY2023	casi	Reduction In Carrying Amount Of Right Of Use Assets ReductionInCarryingAmountOfRightOfUseAssets	988000
CY2022	casi	Reduction In Carrying Amount Of Right Of Use Assets ReductionInCarryingAmountOfRightOfUseAssets	1189000
CY2021	casi	Reduction In Carrying Amount Of Right Of Use Assets ReductionInCarryingAmountOfRightOfUseAssets	1280000
CY2022	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-2058000
CY2021	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-65000
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	8724000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	7217000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	7010000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	7770000
CY2021	casi	Research And Development In Process Acquired ResearchAndDevelopmentInProcessAcquired	6555000
CY2021	casi	Government Grant GovernmentGrant	-472000
CY2023	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-581000
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-8895000
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	5660000
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-48000
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-846000
CY2023	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	474000
CY2022	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	5325000
CY2023	casi	Impairment Loss Of Long Term Investments ImpairmentLossOfLongTermInvestments	-2009000
CY2021	casi	Impairment Loss Of Long Term Investments ImpairmentLossOfLongTermInvestments	-865000
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3422000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3170000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5158000
CY2023	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	587000
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9739000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4231000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	551000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-701000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1383000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1303000
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1149000
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1066000
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1491000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-876000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-912000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2303000
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-1888000
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	1980000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19967000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21088000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26842000
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	138000
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	10000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	204000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5612000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8945000
CY2022	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	3731000
CY2022	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	33891000
CY2023	casi	Purchase Of Short Term Investments And Term Deposits PurchaseOfShortTermInvestmentsAndTermDeposits	51754000
CY2022	casi	Purchase Of Short Term Investments And Term Deposits PurchaseOfShortTermInvestmentsAndTermDeposits	4527000
CY2023	casi	Proceeds From Sales Or Maturity Of Short Term Investments And Term Deposits ProceedsFromSalesOrMaturityOfShortTermInvestmentsAndTermDeposits	43322000
CY2022	casi	Proceeds From Government Grant ProceedsFromGovernmentGrant	6436000
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2037000
CY2023	casi	Proceeds From Extinguishment Of Investment In Convertible Loan ProceedsFromExtinguishmentOfInvestmentInConvertibleLoan	1000000
CY2021	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	6555000
CY2021	casi	Receipt Of Repayment Of Convertible Note ReceiptOfRepaymentOfConvertibleNote	172000
CY2021	casi	Receipt Of Government Grant ReceiptOfGovernmentGrant	474000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9673000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	31159000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20691000
CY2022	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	4001000
CY2021	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	709000
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	4001000
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1548000
CY2023	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	738000
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	278000
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	3267000
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2019000
CY2021	casi	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	32500000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	109000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-907000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3267000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29642000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	518000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1604000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-469000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-30029000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8408000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-18360000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	47112000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	38704000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	57064000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17083000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	47112000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	38704000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	62000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	42000
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1807000
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	99000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	44000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3288000
CY2023	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	18895000
CY2021	casi	Non Cash Investing Loan Forgiveness NonCashInvestingLoanForgiveness	472000
CY2023	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. DESCRIPTION OF BUSINESS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Nature of Operations and Organization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CASI Pharmaceuticals, Inc. (“CASI” or the “Company”) (Nasdaq: CASI) is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company was incorporated in 1991, and in 2012, with new leadership, the Company shifted its business strategy to China and has since built an infrastructure in China that includes sales and marketing, medical affairs, regulatory and clinical development and in the foreseeable future, manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is focused on acquiring, developing and commercializing products that augment our hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company is executing its plan to become a biopharmaceutical leader by launching medicines in the greater China market, leveraging its China-based regulatory, clinical and commercial competencies and its global drug development expertise. The majority of the Company’s operations and activities are now located in China and are conducted primarily through two subsidiaries: (i) CASI Pharmaceuticals (China) Co., Ltd. (“CASI China”), which is wholly owned and is located in Beijing, China, and (ii) CASI Pharmaceuticals (Wuxi) Co., Ltd. (“CASI Wuxi”), which is located in Wuxi, China. CASI China is primarily responsible for the day-to-day operations, and oversee the Company’s commercial activities throughout China. CASI Wuxi is part of the long-term strategy to support the Company’s future clinical and commercial manufacturing needs, to manage its supply chain for certain products, and to develop a GMP manufacturing facility in China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 31, 2023, CASI Pharmaceuticals, Inc., the Delaware corporation (“CASI Delaware”) and CASI Pharmaceuticals Holdings, Inc., an exempted company incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of the Company (“CASI Cayman”) entered into a definitive agreement and plan of merger (the “Merger Agreement”) related to a proposed merger transaction. The Merger Agreement provides that, upon the terms and subject to the conditions set forth therein, CASI Delaware will merge with and into CASI Cayman (the “Redomicile Merger”), with CASI Cayman surviving and changing its name to CASI Pharmaceuticals, Inc. Following the Redomicile Merger, CASI Cayman, together with its subsidiaries, owns and continues to conduct the Company’s business in substantially the same manner as is currently being conducted by the Company and its subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement and the Redomicile Merger were approved by the stockholders of CASI Delaware at a special meeting of stockholders held on March 20, 2023. The Merger Agreement was filed with CASI Cayman’s Registration Statement on Form F-4 filed with the Securities and Exchange Commission (the “SEC”) on January 31, 2023 (the “Registration Statement”) and CASI Cayman’s prospectus filed with the SEC on February 14, 2023 (the “Prospectus”). The Merger Agreement and Redomicile Merger is described in details in CASI Cayman’s proxy statement/prospectus filed with the SEC on January 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 21, 2023, CASI Delaware and CASI Cayman completed the Redomicile Merger. Each issued and outstanding stock of CASI Delaware’s common stock was converted to one ordinary share of CASI Cayman. The consolidated financial statements of CASI Cayman represents the continuation of the financial statements of CASI Delaware, reflecting the assets and liabilities, accumulated deficit, and other equity balances of CASI Delaware before the Redomicile Merger. The equity structure is restated using the exchange ratio established in the Merger Agreement to reflect the number of shares of CASI Cayman.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Business Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company has built a fully integrated, world class biopharmaceutical company dedicated to the successful development and commercialization of innovative and other therapeutic products. Its business development strategy is currently focused on acquiring additional targeted drugs and immuno-oncology therapeutics through licensing that will expand its hematology/oncology franchise. The Company uses a market-oriented approach to identify pharmaceutical/biotechnology candidates that it believes to have the potential for gaining widespread market acceptance, either globally or in China, and for which development can be accelerated under its global drug development strategy. In many cases its business development strategy includes direct equity investments in the licensor company. The Company intends for its pipeline to reflect a diversified and risk-balanced set of assets that include (1) late-stage clinical drug candidates in-licensed for China or global regional rights, (2) proprietary or licensed innovative drug candidates, and (3) select high quality </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">pharmaceuticals that fit its therapeutic focus. The Company has focused on US/EU approved product candidates, and product candidates with proven targets or product candidates that have reduced clinical risk with a greater emphasis on innovative therapeutics. Although oncology with a focus on hematological malignancies is its principal clinical and commercial target, the Company is opportunistic about other therapeutic areas that can address unmet medical needs. The Company will continue to pursue building a robust pipeline of drug candidates for development and commercialization in China as its primary market, and if rights are available for the rest of the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company believes its China operations offer a significant market and growth potential due to the extraordinary increase in demand for high quality medicines coupled with regulatory reforms in China that facilitate the entry of new pharmaceutical products into the country. The Company will continue to in-license clinical-stage and late-stage drug candidates, and leverage its cross-border operations and expertise, and hope to be the partner of choice to provide access to the China market. The Company expects the implementation of its plans will include leveraging its resources and expertise in both the U.S. and China so that the Company can maximize regulatory, development and clinical strategies in both countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company launched its first commercial product, EVOMELA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (Melphalan for Injection) in China in August 2019. In China, EVOMELA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> is approved for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. EVOMELA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup>, was originally licensed from Spectrum Pharmaceuticals, Inc. (“Spectrum”) and it had a supply agreement with Spectrum to support its application for import drug registration and for commercialization purposes. Spectrum completed the sale of its portfolio of FDA-approved hematology/oncology products including EVOMELA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> to Acrotech Biopharma L.L.C. (“Acrotech”) on March 1, 2019. The original supply agreement with Spectrum was assumed by Acrotech.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July 31, 2023, the Company entered into a tripartite assignment agreement (the “FOLOTYN<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">® </sup>Assignment Agreement”) with Mundipharma International Corporation Limited (“MICL”), Mundipharma Medical Company (“MMCo”) and Acrotech Biopharma Inc. (“Acrotech Inc.”), pursuant to which, MICL’s rights and obligations under that certain License, Development and Commercialization Agreement (as amended and restated) dated as of May 29, 2013 for the commercialization of FOLOTYN<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (Pralatrexate) in China, with certain terms of such rights and obligations amended as agreed to by the parties, is assigned to the Company. FOLOTYN<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (Pralatrexate) is a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (“PTCL”). This product was approved by both the FDA and China’s NMPA for PTCL. The Company announced the first patient received FOLOTYN<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> treatment in China on February 15, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The other core hematology/oncology assets in the Company’s pipeline include:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">·</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">CNCT19</i> is an autologous CD19 CAR-T investigative product (“CNCT19”) being developed by the Company’s partner Juventas for which it has exclusive worldwide co-commercial and profit-sharing rights. CNCT19 is being developed as a potential treatment for patients with hematological malignancies which express CD19 including, B-cell acute lymphoblastic leukemia (“B-ALL”) and B-cell non-Hodgkin lymphoma (“B-NHL”). CNCT19 targets CD19, a B-cell surface protein widely expressed during all phases of B-cell development and a validated target for B-cell driven hematological malignancies. CD19 targeted CAR constructs from several different institutions have demonstrated consistently high antitumor efficacy in children and adults with relapsed B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and B-cell non-Hodgkin lymphoma (B-NHL). In November 2023, The NMPA has granted market approval for Juventas' investigational cell therapy, CNCT19 (Inaticabtagene Autoleucel), for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in China.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">·</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">BI-1206 </i>In October 2020, the Company entered into an exclusive licensing agreement with BioInvent International AB (“BioInvent”) for the development and commercialization of novel anti-FcγRIIB antibody, BI-1206, in Mainland China, Taiwan, Hong Kong and Macau. BioInvent is a biotechnology company focused on the discovery and development of first-in-class immune-modulatory antibodies for cancer immunotherapy. BI-1206 is being investigated in a Phase 1/2 trial, in combination with anti-PD1 therapy Keytruda<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (pembrolizumab), in patients with solid tumors, and in a Phase 1/2a trial in combination with MabThera<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (rituximab) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). CTA was approved by China NMPA in December 2021 and ethics committee approvals have been received in January of 2022. The Company obtained approval from China Human Genetic Resources Administrative Office (“HGRAO”) in April 2022. The Company is planning a Phase 1 study of BI-1206 in combination with rituximab with a single agent BI-1206 run in phase in patients with NHL (mantle cell lymphoma, marginal zone lymphoma, and follicular lymphoma) to assess PK, safety and tolerability, select the Recommended Phase 2 Dose and assess early signs of clinical efficacy as part of its </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">development program for BI-1206 in China. The study received regulatory approval from the China Center for Drug Evaluation (“CDE”) in the second quarter of 2022, and the first patient was enrolled and dosed in the third quarter of 2022. </p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">·</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">CB-5339 </i>is a novel VCP/p97 inhibitor focused on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies. The Company entered into an exclusive license on March 21, 2021 with Cleave Therapeutics, Inc. (“Cleave”) for the development and commercialization of CB-5339 in Mainland China, Hong Kong, Macau and Taiwan. CB-5339, an oral second-generation, small molecule VCP/p97 inhibitor, has been evaluated in a Phase 1 clinical trial in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The Company submitted the CB-5339 CTA application for the multiple myeloma indication in March 2022 and received approval from the NMPA in January 2023.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">·</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">CID-103 </i>is a full human IgG1 anti-CD38 monoclonal antibody recognizing a unique epitope that has demonstrated an encouraging preclinical efficacy and safety profile compared to other anti-CD38 monoclonal antibodies, and which the Company has exclusive global rights. CID-103 is being developed for the treatment of patients with multiple myeloma. The Phase 1 dose escalation and expansion study of CID-103, in patients with previously treated, relapsed or refractory multiple myeloma is closed to further accrual in France and the UK. </p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">·</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">Thiotepa</i> is a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. Thiotepa has a long history of established use in the hematology/oncology setting. The Company is applying for generic registration and, subject to regulatory and marketing approvals.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Since its inception in 1991, the Company has incurred significant losses from operations and, as of December 31, 2023, has incurred an accumulated deficit of $660.8 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company believes that it has sufficient resources to fund its operations at least one year beyond the date that the consolidated financial statements are issued. As of December 31, 2023, the Company had a balance of cash and cash equivalents of $17.1 million, short term investments of $12.0 million, of which $14.4 million was held in the financial institutions in the mainland China and Hong Kong. The Company intends to continue to exercise tight controls over operating expenditures and will continue to pursue opportunities, as required, to raise additional capital and will also actively pursue non- or less-dilutive capital raising arrangements or opportunities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">License and Distribution Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">EVOMELA</i><sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">®</sup><i style="font-style:italic;"> License Arrangements with Acrotech</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has product rights and perpetual exclusive licenses from Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (Melphalan Hydrochloride For Injection) in the greater China region (which includes Mainland China, Taiwan, Hong Kong and Macau). As well the Company had similar rights to assets ZEVALIN<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (Ibritumomab Tiuxetan) and MARQIBO<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (Vincristine Sulfate Liposome Injection). The exclusive licenses held by the Company were originally licensed from Spectrum Pharmaceuticals Cayman, LP Inc. (“Spectrum”), and Spectrum completed the sale of its portfolio of FDA-approved hematology/oncology products including EVOMELA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> to Acrotech on March 1, 2019. On December 3, 2018, the Company received NMPA’s approval for importation, marketing and sales in China and in August 2019 the Company launched commercial sales EVOMELA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> in China. The NMPA required EVOMELA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">® </sup>post-marketing study has been completed and the clinical study report has been submitted to CDE for review and comment. In May 2022, Acrotech and the Company agreed to terminate the license agreement with respect to MARQIBO<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> and ZEVALIN<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">FOLOTYN</i><sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">®</sup><i style="font-style:italic;"> (Pralatrexate) License Agreement with MICL, MMCo and Acrotech Inc.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35pt;margin:0pt 0pt 12pt 0pt;">On July 31, 2023, the Company entered into a tripartite assignment agreement (the “FOLOTYN<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">® </sup>Assignment Agreement”) with MICL, MMCo and Acrotech Inc., pursuant to which, MICL’s rights and obligations under that certain License, Development and Commercialization Agreement (as amended and restated) dated as of May 29, 2013 for the commercialization of FOLOTYN<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (Pralatrexate) in China, with certain terms of such rights and obligations amended as agreed to by the parties, is assigned to the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35pt;margin:0pt 0pt 12pt 0pt;">In relation to the FOLOTYN<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">® </sup>Assignment Agreement, the Company and MICL entered into a payment agreement (the “Payment Agreement”), pursuant to which the Company will pay MICL a total of US$ 12 million, including (i) a one-time payment of US$ 2 million which will be paid upon completion of the quality audit; (ii) a one time, non-refundable and non-creditable payment of US$ 2 million to be paid when the aggregate net sales of FOLOTYN<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> in China equals to or exceeds US$ 30,000,000, and (iii) in each calendar quarter, a one-time, non-refundable and non-creditable payment of an amount equal to 10% of net sales of FOLOTYN<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> in China in the preceding calendar quarter, until an aggregate amount of US$ 8 million is paid in such quarterly instalments. In the event that the Company has not paid the full amount of payment of US$10 million under (ii) and (iii) above (the “Deferred Payments”) on July 31, 2028, the remaining amount shall become immediately due and payable, unless the drug approval in China is not renewed by relevant regulatory authorities. The initial drug approval of FOLOTYN<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> in China is effective until August 2025 and the renewal of drug license is subject to satisfaction of certain requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35pt;margin:0pt 0pt 12pt 0pt;">Concurrently with the execution of the FOLOTYN<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">® </sup>Assignment Agreement and the Payment Agreement, the parties entered into certain other agreements in relation to the commercialization of FOLOTYN<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup>, including a supply agreement entered into by and between the Company and Acrotech Inc., pursuant to which Acrotech Inc. will supply to the Company FOLOTYN<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> subject to terms and on the conditions set forth therein. The Company is obligated to pay Acrotech Inc. additional $750,000 in three instalments when certain conditions are met. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35pt;margin:0pt 0pt 12pt 0pt;">The Company announced the first patient received FOLOTYN<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> treatment in China on February 15, 2024. The Company will continue to spend time, resources and efforts on the commercialization of FOLOTYN<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> in China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;background:#ffffff;">China Resources Pharmaceutical Commercial Group International Trading Co., Ltd. (previously known as China Resources Guokang Pharmaceuticals Co., Ltd.)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2019, the Company entered into a three-year exclusive distribution agreement with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd. (“CRPCGIT”) to appoint CRPCGIT on an exclusive basis as its distributor to distribute EVOMELA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">® </sup>in the territory of the People’s Republic of China (excluding Hong Kong, Taiwan and Macau), subject to certain terms and conditions. The Company’s internal marketing and sales team are responsible for commercial activities, including, for example, direct interaction with therapeutic area experts, physicians, hospital centers and the generating of sales. The agreement was renewed in March 2022 for two years, and further extended in February 2024 for an additional three years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">C</i><i style="font-style:italic;">hina National Medicines Corporation Ltd.</i> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 6, 2023, the Company entered into an Exclusive Distribution Agreement (the “Agreement”) with China National Medicines Corporation Ltd. (“CNMC”) and CASI China. Under the terms of the Agreement, the Company appointed CNMC on an exclusive basis as its sole distributor for the sale of Pralatrexate for Injection (Folotyn<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup>) in the territory of the People’s Republic of China (excluding Hong Kong, Taiwan and Macau) (the “Territory”) during the term of one year, subject to certain terms and conditions. CNMC may appoint sub-distributors of its choice in furtherance of this goal provided that the Company has been notified in writing and received the due diligence or any other information of the sub-distributor as the Company requests. CASI China is authorized to coordinate and communicate with parties to the Agreement and provide supports for the performance of the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Precision Autoimmune Therapeutics Co., Ltd., (previously known as Beijing Tianshi Tongda Pharmaceuticals Technology Co., Ltd)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In May 2022, the Company entered into a Sublicense Agreement (the “Sublicense Agreement”) with Precision Autoimmune Therapeutics Co., Ltd. (“PAT”), a company established under the laws of China, pursuant to which the Company granted PAT an exclusive (subject to the commercialization and co-marketing rights), perpetual, worldwide license, with the right to freely grant further sublicenses subject to terms and conditions in the Sublicense Agreement, for the investigational anti-CD38 monoclonal antibody TSK011010 licensed and controlled by the Company from Black Belt Therapeutics Limited, in the treatment, prevention and diagnosis </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of autoimmune diseases, conditions and disorders in humans. Pursuant to the Sublicense Agreement, PAT will make an upfront payment of $10.0 million equivalent in two equal instalments upon completion of its first and second financing, respectively, plus potential future payments or reimbursement of development and sales milestones and royalties to the Company. The Company received the first installment in the amount of $5.0 million in 2022 and recognized it as sublicense revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Also in May 2022, CASI Pharmaceuticals (China) Co., Ltd. (“CASI China”) entered into an agreement for the investment in PAT in the amount of RMB 20.0 million (approximately $3.0 million) in cash during PAT’s first equity financing (see Note 3).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Juventas Cell Therapy Ltd. (“Juventas”)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2019, the Company entered into a license agreement for exclusive worldwide license to commercialize an autologous anti-CD19 T-cell therapy product (CNCT19) from Juventas (the “Exclusive License Agreement”). Juventas is a China-based company engaged in cell therapy. The terms of the agreement include RMB 70 million ($10 million) of milestone payments upon the registration of Phase II clinical trial of CNCT19 and sales royalty payments. The milestone was met during the third quarter of 2020, the Company paid the milestone payment of RMB 70 million to Juventas in September 2020, and recognized it as acquired in-process research and development expenses in the consolidated statement of operations and comprehensive loss in 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2020, Juventas and its shareholders (including CASI Biopharmaceuticals (Wuxi) Co., Ltd (“CASI Biopharmaceuticals”), a subsidiary of the Company, ) agreed to certain terms and conditions required by a new third-party investor to facilitate the Series B financing of Juventas, pursuant to which the Company agreed to amend and supplement the original “licensing agreement (the "Supplementary Agreement") by agreeing to pay Juventas certain percentage of net profits generated from commercial sales of CNCT19 in addition to the royalty fee payment calculated as a percentage of net sales. The Supplementary Agreement also specifies a minimum annual target net profit to be distributed to Juventas and certain other terms and obligations. In return, the Company obtained additional equity interests in Juventas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Supplementary Agreement, Juventas and the Company will jointly market CNCT19, including, but not limited to, establishing medical teams, developing medical strategies, conducting post-marketing clinical studies, establishing Standardized Cell Therapy Centers, establishing and training providers with respect to cell therapy, testing for cell therapy, and monitoring quality controls (cell collection and transfusion, etc.), and patient management (adverse reactions treatment, patients’ follow-up visits, and establishment of a database). The Company also will reimburse Juventas for a portion of Juventas’ marketing expenses as reviewed and approved by a joint commercial committee to be constituted. The Company will continue to be responsible for recruiting and establishing a sales team to commercialize CNCT19.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2022, CASI Biopharmaceuticals entered into an Equity Transfer Agreement to transfer its equity interest in Juventas in the amount of RMB 240.9 million (approximately $33.9 million) to a limited partnership enterprise (see Note 3). The Exclusive License Agreement is still effective after this equity transfer.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 2, 2024, CASI received a notice from Juventas, which purported to terminate the CNCT19 Agreements. CASI responded to Juventas’ purported termination notice, noting that Juventas was not entitled to unilaterally terminate the CNCT19 Agreements and further demanding that Juventas cease any conduct that may constitute further breach of the CNCT19 Agreements and execute a written undertaking regarding compliance with the CNCT19 Agreements by March 13, 2024. Juventas did not comply with CASI’s demands. On March 20, 2024, CASI submitted a Notice of Arbitration at the Hong Kong International Arbitration Centre (“HKIAC”) against Juventas pursuant to the CNCT19 Agreements’ dispute resolution clauses, claiming that Juventas’ purported termination was invalid and that Juventas breached the CNCT19 Agreements and seeking, among other things, damages and injunctive reliefs. Together with the Notice of Arbitration, CASI also submitted an application for the appointment of an emergency arbitrator, seeking emergency injunctive reliefs. On the same day, Juventas also submitted a Notice of Arbitration at the HKIAC against CASI, alleging, among other things, that the CNCT19 Agreements were validly terminated and that CASI breached the CNCT19 Agreements. The HKIAC has appointed an emergency arbitrator in accordance with CASI’s application. The arbitration proceedings are in their early stages and the Company cannot predict right now the outcome of either of these proceedings. If we do not prevail in either of these proceedings completely or in part, or fail to reach a favorable settlement with Juventas, our plan with respect to the commercialization of CNCT 19 may be delayed or otherwise adversely impacted, which may in turn result in adverse impacts on our results of operations, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">BioInvent International AB </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2020, the Company entered into an exclusive licensing agreement with BioInvent International AB (“BioInvent”) for the development and commercialization of novel anti-FcγRIIB antibody, BI-1206, in Mainland China, Taiwan, Hong Kong and Macau. BioInvent is a biotechnology company focused on the discovery and development of first-in-class immune-modulatory antibodies for cancer immunotherapy. BI-1206 is being investigated in a Phase 1/2 trial, in combination with anti-PD1 therapy Keytruda<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (pembrolizumab), in patients with solid tumors, and in a Phase 1/2a trial in combination with MabThera<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (rituximab) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). The CASI Clinical Trial Application (CTA) was approved by China National Medical Products Administration (NMPA) in December 2021 and ethics committee approvals have been received in January of 2022. The Company obtained approval from HGRAO in April 2022. The Company is planning a Phase 1 study of BI-1206 in combination with rituximab with a single agent BI-1206 run in phase in patients with NHL (mantle cell lymphoma, marginal zone lymphoma, and follicular lymphoma) to assess PK, safety and tolerability, select the Recommended Phase 2 Dose and assess early signs of clinical efficacy as part of its development program for BI-1206 in China. The study received regulatory approval from the China Center for Drug Evaluation (“CDE”) in the second quarter of 2022, and the first-patient dosing was achieved in the third quarter of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the agreement, BioInvent and CASI will develop BI-1206 in both hematological malignancies and solid tumors, with CASI responsible for commercialization in China and associated markets. CASI made a<span style="color:#212529;"> </span><span style="color:#212529;">$5.9</span><span style="color:#212529;"> </span>million upfront payment in November 2020 to BioInvent and will pay up to<span style="color:#212529;"> </span><span style="color:#212529;">$83</span><span style="color:#212529;"> million in development and commercial milestone payments plus tiered royalties in the high-single to mid-double-digit range on net sales of BI-1206. Because BI-1206 underlying the acquired rights has not reached technological feasibility and has no alternative future uses, the Company expensed </span><span style="color:#212529;">$5.9</span><span style="color:#212529;"> </span>million as acquired in-process research and development in 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In conjunction with the license agreement entered into with BioInvent, the Company made a SEK 53.8 million investment in 1.2 million new shares of BioInvent, and 588,000 new warrants, each warrant with a right to subscribe for 1 new share in BioInvent within a period of five years and at a subscription price of SEK 78.50 per share. In the second quarter of 2022, the Company sold 275,000 ordinary shares of BioInvent for $1.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Black Belt Therapeutics Limited</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2019, the Company entered into a license agreement with Black Belt Therapeutics Limited (“Black Belt”) for exclusive worldwide rights to CID-103, an investigational anti-CD38 monoclonal antibody (Mab) (formerly known as TSK011010). The Company expects that its clinical materials and commercial inventory will be supplied by one or more contract manufacturers with whom the Company has contracted with. Under the terms of the agreement, CASI obtained global rights to CID-103 for an upfront payment of 5 million euros (approximately US$5.7 million) and would pay up to 2.75 million euros (approximately $2.93 million) and $40.75 million in development milestone payments and certain royalties based on sales milestones. In June 2021, the Company achieved the First-Patient-In (FPI) in the Phase 1 dose escalation and expansion study of CID-103, and made US$750,000 milestone payment in June 2021 and €250,000 (approximately $305,000) payment in August 2021 under the terms of the agreement. Because CID-103 underlying the acquired rights has not yet reached technological feasibility and has no alternative uses, the Company expensed 5 million euros and $1.1 million as acquired in-process research and development, respectively, in 2019 and 2021. As mentioned above, in May 2022, the Company entered into the Sublicense Agreement to grant PAT an exclusive, perpetual, worldwide license, for the investigational anti-CD38 monoclonal antibody TSK011010.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cleave Therapeutics, Inc. </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2021, the Company entered into an exclusive license with Cleave Therapeutics, Inc. (“Cleave”) for the development and commercialization of CB-5339, an oral novel VCP/p97 inhibitor, in both hematological malignancies and solid tumors, in Mainland China, Hong Kong, Macau and Taiwan. Cleave is a clinical-stage biopharmaceutical company focused on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response and other cellular stress pathways for therapeutic use in the treatment of patients with cancer. Cleave and the Company will develop CB-5339 in both hematological malignancies and solid tumors, with CASI responsible for development and commercialization in China and associated markets. The Company paid a $5.5 million upfront payment to Cleave in 2021 and will pay up to $74 million in development and commercial milestone payments plus tiered royalties in the high-single to mid-double-digit range on net sales of CB-5339.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CB-5339 has been evaluated by Cleave in a Phase 1 clinical trial in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Because CB-5339 has not yet reached technological feasibility and has no alternative future uses, the Company expensed the $5.5 million upfront payment as acquired in-process research and development in 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July 18, 2023, the Company entered into an assignment agreement (the “Cleave Assignment Agreement”) with Cleave, pursuant to which the Company obtained the global intellectual property rights related to CB-5339. The Assignment Agreement terminates and supersedes the License Agreement for CB-5339 the Company previously entered into with Cleave. Pursuant to the Assignment Agreement and partially in exchange for the transfer of the global intellectual property rights for CB-5339 as well as all remaining CB-5339 drug substance and drug product to the Company and a repayment in the amount of USD $1 million to the Company, the Company agreed to the termination of that certain outstanding convertible promissory note issued by Cleave to the Company in 2021 with a principal amount of USD $5.5 million. The fair value of the global intellectual property rights and drug substance/product is immaterial. Cleave is also eligible to receive up to US$66 million in commercial and sales milestone payments, plus a 2.5% royalty on net sales of CB-5339 and any other VCP/p97 inhibitor covered by the Assignment Agreement, in each case subject to the terms and on the conditions set forth in the Assignment Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Pharmathen Global BV</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 29, 2019, the Company entered into an exclusive distribution agreement with Pharmathen Global BV (“Pharmathen”) for the development and distribution of octreotide long acting injectable (Octreotide LAI) microsphere in China. Octreotide LAI formulations, which are approved in various European countries, are considered a standard of care for the treatment of acromegaly and the control of symptoms associated with certain neuroendocrine tumors. The Company paid and expensed an upfront payment of 1 million euros ($1.1 million) in 2019 and milestone payment of 1.5 million euros ($1.7 million) in 2020 with achievements of certain milestones. In the first quarter of 2023, the Company entered into a Termination Agreement and Release with Pharmathen, pursuant to which both parties agreed to terminate the 2019 exclusive distribution license agreement with respect to product Octreotide LAI, and Pharmathen refunded 1.25 million euros ($1.3 million) to the Company which is recorded in other operating income on the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Riemser Pharma GmbH</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In August 2019, the Company entered into a distribution agreement in China with Riemser Pharma GmbH (“Riemser”) to a novel formulation of thiotepa, a chemotherapeutic agent, which has multiple potential indications including use as a conditioning treatment for use prior to allogenic hematopoietic stem cell transplantation. Thiotepa has a long history of established use in the hematology/oncology setting. Pursuant to the distribution agreement, CASI obtained the exclusive distribution right of the products in China, and Riemser will be responsible for manufacturing and supplying CASI with clinical materials and commercial inventory. The Company is applying for generic registration and, subject to regulatory and marketing approvals, the Company intends to advance and commercialize this product in China. In January 2020, Riemser was acquired by Esteve Healthcare, S.L. (“ESTEVE”), an international pharmaceutical company headquartered in Barcelona, Spain. In November 2022, the Company entered into an Amendment with Esteve, pursuant to which the Company and Esteve will equally share the costs of clinical trials (if any) for the registration of Thiotepa in China. After the product is launched, the Company will be subject to annual minimum purchase as prescribed in the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p>
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-660800000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17100000
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	12000000.0
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company’s significant </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">accounting estimates relate to recoverability of property, plant and equipment, right of use assets, intangible assets and long-term investments, valuation allowance for deferred tax assets, share-based arrangements and fair value of investments. Management bases its estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances. Actual results may differ from those estimates, and such differences may be material to the consolidated financial statements.</p>
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations Risks </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cash Concentration Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company maintains its U.S., Hong Kong dollar and RMB cash in bank deposit accounts, which, at times, may exceed regulated insured limits. The Company believes it is not exposed to significant credit risk on cash and cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Vendor Concentration Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has a sole supplier, Acrotech, for its EVOMELA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">® </sup> and FOLOTYN<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">® </sup>products. The Company’s ability to select other providers of EVOMELA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">® </sup> and FOLOTYN<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">® </sup>is limited by FDA regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Geographic Concentration Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.4pt;margin:0pt 0pt 12pt 0pt;">The Company revenue is solely generated in mainland China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Accounts Receivable and Credit Concentration</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CRPCGIT is the sole customer of the Company's EVOMELA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">® </sup> product sales in China. All consolidated product sales for the years ended December 31, 2023, 2022 and 2021 were generated from sales to CRPCGIT in China, and all the Company’s accounts receivable balance as of December 31, 2023 and 2022 were due from CRPCGIT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company extends credit to CRPCGIT on an unsecured basis and does not believe there is significant credit risk.</p>
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss	11698000
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss	1462000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	313000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	12011000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1462000
CY2023Q4	us-gaap	Debt Securities Trading And Equity Securities Fv Ni Cost DebtSecuritiesTradingAndEquitySecuritiesFvNiCost	3167000
CY2023	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	35000
CY2023	casi	Debt And Equity Securities Unrealized Gain Loss Including Impairment DebtAndEquitySecuritiesUnrealizedGainLossIncludingImpairment	-1516000
CY2023Q4	us-gaap	Trading Securities Debt TradingSecuritiesDebt	1686000
CY2022Q4	us-gaap	Debt Securities Trading And Equity Securities Fv Ni Cost DebtSecuritiesTradingAndEquitySecuritiesFvNiCost	8667000
CY2022	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	20000
CY2022	casi	Debt And Equity Securities Unrealized Gain Loss Including Impairment DebtAndEquitySecuritiesUnrealizedGainLossIncludingImpairment	-6375000
CY2022Q4	us-gaap	Trading Securities Debt TradingSecuritiesDebt	2312000
CY2023Q4	us-gaap	Inventory Net InventoryNet	15900000
CY2022Q4	us-gaap	Inventory Net InventoryNet	6100000
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	0
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	0
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	0
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	1100000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1300000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1500000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	0
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	0
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	0
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2392000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1398000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	728000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	868000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1616000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	476000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2344000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1344000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1042000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1157000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	1354000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	518000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	421000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1525000
CY2023	casi	Right Of Use Assets Remeasured RightOfUseAssetsRemeasured	1506000
CY2023	casi	Number Of Operating Leases NumberOfOperatingLeases	7
CY2022	casi	Number Of Operating Leases NumberOfOperatingLeases	6
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y6M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y6M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0402
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0355
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	727000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	505000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	388000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	350000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	350000
CY2023Q4	casi	Lessee Operating Lease Liability Payments Due Thereafter LesseeOperatingLeaseLiabilityPaymentsDueThereafter	262000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2582000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	238000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2344000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	728000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1616000
CY2023Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	7190000
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	7161000
CY2023Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	5997000
CY2022Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	619000
CY2023Q4	casi	Furniture And Equipment Gross FurnitureAndEquipmentGross	682000
CY2022Q4	casi	Furniture And Equipment Gross FurnitureAndEquipmentGross	622000
CY2023Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	23000
CY2022Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	5728000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13892000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14130000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4651000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2299000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9241000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11831000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2500000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1200000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	500000
CY2021	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0
CY2022	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0
CY2023	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0
CY2022	casi	Number Of Abbreviated New Drug Applications NumberOfAbbreviatedNewDrugApplications	6
CY2022	casi	Number Of Abbreviated New Drug Applications NumberOfAbbreviatedNewDrugApplications	6
CY2023Q4	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P1Y
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2302000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	463000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1839000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16076000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6289000
CY2022Q4	casi	Finite Lived Intangible Assets Accumulated Impairment FiniteLivedIntangibleAssetsAccumulatedImpairment	8724000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1063000
CY2023Q4	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	753000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	728000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	868000
CY2023Q4	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	481000
CY2022Q4	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	150000
CY2023Q4	casi	Payables Related To Property And Equipment Current PayablesRelatedToPropertyAndEquipmentCurrent	99000
CY2022Q4	casi	Payables Related To Property And Equipment Current PayablesRelatedToPropertyAndEquipmentCurrent	44000
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	538000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1063000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12203000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	13210000
CY2023	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	2064000
CY2022	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	45000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1287000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1211000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1347000
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	8724000
CY2023	us-gaap	Finite Lived Intangible Assets Foreign Currency Translation Gain Loss FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	1000
CY2022	us-gaap	Finite Lived Intangible Assets Foreign Currency Translation Gain Loss FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	1250000
CY2021	us-gaap	Finite Lived Intangible Assets Foreign Currency Translation Gain Loss FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	-340000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1839000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1063000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12203000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1055000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	707000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	11000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	11000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	11000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	44000
CY2023Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	3124000
CY2022Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	2911000
CY2023Q4	casi	Grants Related To Land Use Right Current GrantsRelatedToLandUseRightCurrent	2543000
CY2022Q4	casi	Grants Related To Land Use Right Current GrantsRelatedToLandUseRightCurrent	2617000
CY2023Q4	casi	Sales And Marketing Services Payable Current SalesAndMarketingServicesPayableCurrent	1985000
CY2022Q4	casi	Sales And Marketing Services Payable Current SalesAndMarketingServicesPayableCurrent	2481000
CY2023Q4	casi	Professional Consulting Service Payable Current ProfessionalConsultingServicePayableCurrent	1023000
CY2022Q4	casi	Professional Consulting Service Payable Current ProfessionalConsultingServicePayableCurrent	705000
CY2023Q4	casi	Clinical Study Service Payable Current ClinicalStudyServicePayableCurrent	1014000
CY2022Q4	casi	Clinical Study Service Payable Current ClinicalStudyServicePayableCurrent	1392000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	648000
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	12288000
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	11816000
CY2023Q4	casi	Profit Sharing Liability Non Current ProfitSharingLiabilityNonCurrent	11821000
CY2022Q4	casi	Profit Sharing Liability Non Current ProfitSharingLiabilityNonCurrent	11821000
CY2023Q4	casi	Interest And Dividends Payable Non Current InterestAndDividendsPayableNonCurrent	2045000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1616000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	476000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	15482000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	12297000
CY2021Q3	casi	Notes Payable Forgiven NotesPayableForgiven	465595
CY2021Q3	casi	Debt Instrument Decrease Interest Forgiveness DebtInstrumentDecreaseInterestForgiveness	6212
CY2023	us-gaap	Other Income OtherIncome	0
CY2022	us-gaap	Other Income OtherIncome	48000
CY2021	us-gaap	Other Income OtherIncome	51000
CY2023Q4	casi	Number Of Guarantee Agreements NumberOfGuaranteeAgreements	4
CY2023Q4	casi	Investment Return Payable In Installments InvestmentReturnPayableInInstallments	26200000
CY2023	casi	Deemed Dividends Adjustment DeemedDividendsAdjustment	22000
CY2022Q4	us-gaap	Redeemable Noncontrolling Interest Equity Common Carrying Amount RedeemableNoncontrollingInterestEquityCommonCarryingAmount	22358000
CY2021Q4	us-gaap	Redeemable Noncontrolling Interest Equity Common Carrying Amount RedeemableNoncontrollingInterestEquityCommonCarryingAmount	23457000
CY2020Q4	us-gaap	Redeemable Noncontrolling Interest Equity Common Carrying Amount RedeemableNoncontrollingInterestEquityCommonCarryingAmount	22033000
CY2023	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-2602000
CY2022	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-8740000
CY2021	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-700000
CY2023	casi	Accretion Of Redeemable Non Controlling Interest AccretionOfRedeemableNonControllingInterest	-3281000
CY2022	casi	Accretion Of Redeemable Non Controlling Interest AccretionOfRedeemableNonControllingInterest	-9497000
CY2021	casi	Accretion Of Redeemable Non Controlling Interest AccretionOfRedeemableNonControllingInterest	-1512000
CY2023	casi	Redeemable Noncontrolling Interest Equity Common Foreign Currency Translation Adjustments RedeemableNoncontrollingInterestEquityCommonForeignCurrencyTranslationAdjustments	-621000
CY2022	casi	Redeemable Noncontrolling Interest Equity Common Foreign Currency Translation Adjustments RedeemableNoncontrollingInterestEquityCommonForeignCurrencyTranslationAdjustments	-1856000
CY2021	casi	Redeemable Noncontrolling Interest Equity Common Foreign Currency Translation Adjustments RedeemableNoncontrollingInterestEquityCommonForeignCurrencyTranslationAdjustments	612000
CY2023	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	22416000
CY2022Q4	us-gaap	Redeemable Noncontrolling Interest Equity Common Carrying Amount RedeemableNoncontrollingInterestEquityCommonCarryingAmount	22358000
CY2021Q4	us-gaap	Redeemable Noncontrolling Interest Equity Common Carrying Amount RedeemableNoncontrollingInterestEquityCommonCarryingAmount	23457000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	411952
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	275834
CY2022Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	10
CY2022Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	10
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2021Q4	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	10000000
CY2021Q4	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	1250000
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	3734992
	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	2541245
	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	3000000.0
CY2023	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	284623
CY2023	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	500000
CY2023Q1	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	136118
CY2021Q1	casi	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	32500000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	827164
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	45.8
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	209887
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	71.9
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	617277
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	36.9
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	617277
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	36.9
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	617277
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	36.9
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-26960000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-41014000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-36654000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13360185
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13647455
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13610441
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13360185
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13647455
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13610441
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.02
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.01
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.69
CY2023	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	77100
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	100000
CY2021	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	200000
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	4300000
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	4200000
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3100000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	7217000
CY2023	casi	Performance Share Based Compensation Expense PerformanceShareBasedCompensationExpense	1800000
CY2022	casi	Performance Share Based Compensation Expense PerformanceShareBasedCompensationExpense	2700000
CY2021	casi	Performance Share Based Compensation Expense PerformanceShareBasedCompensationExpense	2300000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.90
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.32
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.00
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7577
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.8126
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7664
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.7851
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7569
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.8150
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0345
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0479
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0198
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0271
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0072
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0138
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M19D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M10D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y2M1D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.59
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7455
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.9408
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0345
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0579
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y11M4D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000
CY2023	casi	Share Based Payment Cash Received From Stock Option Exercises ShareBasedPaymentCashReceivedFromStockOptionExercises	100000
CY2021	casi	Share Based Payment Cash Received From Stock Option Exercises ShareBasedPaymentCashReceivedFromStockOptionExercises	0
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	4055164
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P6Y6M21D
CY2023Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	2.24
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	2215814
CY2023Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	2.38
CY2023	casi	Total Unrecognized Share Based Compensation Cost Expected To Be Recognized Over Weighted Average Period TotalUnrecognizedShareBasedCompensationCostExpectedToBeRecognizedOverWeightedAveragePeriod	6200000
CY2023	casi	Unrecognized Share Based Compensation Cost Expected To Be Recognized Over Weighted Average Period UnrecognizedShareBasedCompensationCostExpectedToBeRecognizedOverWeightedAveragePeriod	5500000
CY2023	casi	Unrecognized Share Based Compensation Cost Expected To Recognize Over Weighted Average Period UnrecognizedShareBasedCompensationCostExpectedToRecognizeOverWeightedAveragePeriod	P2Y
CY2023	casi	Unrecognized Share Based Compensation Cost Expected To Be Recognized Over Weighted Average Period Related To Non Probable Condition Options UnrecognizedShareBasedCompensationCostExpectedToBeRecognizedOverWeightedAveragePeriodRelatedToNonProbableConditionOptions	700000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	144000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-12359000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-32169000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-26436000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-25072000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-3673000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-26292000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-37431000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-35842000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	42536000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	65459000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2555000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2931000
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	6609000
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	9492000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6593000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6409000
CY2023Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	870000
CY2022Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	1483000
CY2023Q4	casi	Deferred Tax Assets Tax Deferred Expense Capitalized Research And Development Amortization DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentAmortization	1773000
CY2022Q4	casi	Deferred Tax Assets Tax Deferred Expense Capitalized Research And Development Amortization DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentAmortization	1410000
CY2023Q4	casi	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	586000
CY2022Q4	casi	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	336000
CY2023Q4	casi	Deferred Tax Assets Tax Deferred Expense Impairment Loss Of Long Term Investments DeferredTaxAssetsTaxDeferredExpenseImpairmentLossOfLongTermInvestments	182000
CY2022Q4	casi	Deferred Tax Assets Tax Deferred Expense Impairment Loss Of Long Term Investments DeferredTaxAssetsTaxDeferredExpenseImpairmentLossOfLongTermInvestments	182000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	254000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	368000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	61281000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	85505000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	677000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2565000
CY2022Q4	casi	Deferred Tax Liabilities Royalty Income DeferredTaxLiabilitiesRoyaltyIncome	2086000
CY2023Q4	casi	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	-598000
CY2022Q4	casi	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	-336000
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	79000
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	143000
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	677000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2565000
CY2023	casi	Percentage Of Valuation Allowance Recognized PercentageOfValuationAllowanceRecognized	1
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5521000
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-7860000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-7526000
CY2023	casi	Income Tax Reconciliation Attribute Expiration Amount IncomeTaxReconciliationAttributeExpirationAmount	28281000
CY2022	casi	Income Tax Reconciliation Attribute Expiration Amount IncomeTaxReconciliationAttributeExpirationAmount	7295000
CY2021	casi	Income Tax Reconciliation Attribute Expiration Amount IncomeTaxReconciliationAttributeExpirationAmount	10676000
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-841000
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-1003000
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-147000
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	7264000
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1469000
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1832000
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1059000
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	121000
CY2023	casi	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Options Tax Shortfalls Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareOptionsTaxShortfallsAmount	830000
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-314000
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-138000
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	9000
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-23864000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1854000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-11335000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-81000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1980000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	85505000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	83651000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	94986000
CY2023Q4	casi	Increase Decrease In Deferred Tax Assets IncreaseDecreaseInDeferredTaxAssets	4417000
CY2022Q4	casi	Increase Decrease In Deferred Tax Assets IncreaseDecreaseInDeferredTaxAssets	9149000
CY2021Q4	casi	Increase Decrease In Deferred Tax Assets IncreaseDecreaseInDeferredTaxAssets	-659000
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-28281000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-7295000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-10676000
CY2023Q4	casi	Deferred Tax Assets Foreign Currency Translation Adjustment DeferredTaxAssetsForeignCurrencyTranslationAdjustment	360000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	61281000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	85505000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	83651000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	997000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1440000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2082000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	49000
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	443000
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	642000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	948000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	997000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1440000
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2023	casi	Underpayment Of Taxes Statue Of Limitation Extended Term UnderpaymentOfTaxesStatueOfLimitationExtendedTerm	100000000
CY2021Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	15853658
CY2021Q1	us-gaap	Share Price SharePrice	2.05
CY2021Q1	casi	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	32500000
CY2023Q4	us-gaap	Restricted Investments RestrictedInvestments	3900000

Files In Submission

Name	View Source	Status
0001558370-24-004190-index-headers.html	Edgar Link	pending
0001558370-24-004190-index.html	Edgar Link	pending
0001558370-24-004190.txt	Edgar Link	pending
0001558370-24-004190-xbrl.zip	Edgar Link	pending
casi-20231231.xsd	Edgar Link	pending
casi-20231231x20f.htm	Edgar Link	pending
casi-20231231x20f009.jpg	Edgar Link	pending
casi-20231231x20f010.jpg	Edgar Link	pending
casi-20231231x20f011.jpg	Edgar Link	pending
casi-20231231xex11d1.htm	Edgar Link	pending
casi-20231231xex11d1001.jpg	Edgar Link	pending
casi-20231231xex12d1.htm	Edgar Link	pending
casi-20231231xex12d2.htm	Edgar Link	pending
casi-20231231xex13d1.htm	Edgar Link	pending
casi-20231231xex13d2.htm	Edgar Link	pending
casi-20231231xex15d1.htm	Edgar Link	pending
casi-20231231xex1d1.htm	Edgar Link	pending
casi-20231231xex2d1.htm	Edgar Link	pending
casi-20231231xex2d1_ag001.jpg	Edgar Link	pending
casi-20231231xex2d1_b001.jpg	Edgar Link	pending
casi-20231231xex4d29.htm	Edgar Link	pending
casi-20231231xex4d37.htm	Edgar Link	pending
casi-20231231xex4d38.htm	Edgar Link	pending
casi-20231231xex4d39.htm	Edgar Link	pending
casi-20231231xex4d40.htm	Edgar Link	pending
casi-20231231xex4d41.htm	Edgar Link	pending
casi-20231231xex4d41005.jpg	Edgar Link	pending
casi-20231231xex4d42.htm	Edgar Link	pending
casi-20231231xex4d43.htm	Edgar Link	pending
casi-20231231xex4d44.htm	Edgar Link	pending
casi-20231231xex4d45.htm	Edgar Link	pending
casi-20231231x20f_htm.xml	Edgar Link	completed
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
casi-20231231xex4d46.htm	Edgar Link	pending
casi-20231231xex4d47.htm	Edgar Link	pending
casi-20231231xex4d48.htm	Edgar Link	pending
casi-20231231xex8d1.htm	Edgar Link	pending
casi-20231231xex97d1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
casi-20231231_lab.xml	Edgar Link	unprocessable
casi-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
casi-20231231_cal.xml	Edgar Link	unprocessable
casi-20231231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CASI
CASI Pharmaceuticals, Inc. Stock $casi

2023 Q4 Form 20-F Financial Statement

#000155837024004190 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CASI CASI Pharmaceuticals, Inc. Stock $casi

2023 Q4 Form 20-F Financial Statement

#000155837024004190 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CASI
CASI Pharmaceuticals, Inc. Stock $casi